News
05-07-2009, 05:13 AM
The University of Pittsburgh Cancer Institute (UPCI) will be the primary site for a clinical trial of ABT-888 a drug previously proven in combination treatments to improve chemotherapy's effectiveness by lowering cancer cells' resistance to treatment. This trial will, for the first time, examine ABT-888 as a single agent for patients with cancers related to BRCA 1 or 2 genetic mutations, which predispose patients to breast and ovarian cancers.
More... (http://www.medicalnewstoday.com/articles/149143.php)
More... (http://www.medicalnewstoday.com/articles/149143.php)